The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

In tumorous tissues, the absence of vasculature supportive tissues intimates the formation of
leaky vessels and pores (100 nm to 2 μm in diameter) and the poor lymphatic system offers …

Multidrug resistance (MDR) is the dominant cause of the failure of cancer chemotherapy.
The design of antitumor drugs that are able to evade MDR is rapidly evolving, showing that …

Brain tumors, especially glioblastoma, remain the most aggressive form of all the cancers
because of inefficient diagnosis and profiling. Nanostructures, such as metallic …

Nanomedicines refers to nanotechnology inspired pharmaceutical products often referred to
as 'nanopharmaceuticals.'It has displayed commendable potential in enhancing therapeutic …

Human neuroscience has made remarkable progress in understanding basic aspects of
functional organization; it is a renowned fact that the blood–brain barrier (BBB) impedes the …

The blood–brain barrier (BBB) is a specialized semipermeable structure that highly
regulates exchanges between the central nervous system parenchyma and blood vessels …

Although some tumor has become a curable disease for many patients, involvement of the
central nervous system (CNS) is still a major concern. The blood–brain barrier (BBB), a …

The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain,
hindering treatment of central nervous system (CNS) disorders such as acute ischemic …

Over the past decade, smart and functional biomaterials have escalated as one of the most
rapidly emerging fields in the life sciences because the performance of biomaterials could …